Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9453175 | 1.00 | MIF (0.34) | MIFNR1H2HCRTR2EPHX2 | |
| SCHEMBL7720760 | 1.00 | MIF (0.34) | MIFNR1H2HCRTR2EPHX2 | |
| SCHEMBL5728730 | 1.00 | MIF (0.34) | MIFNR1H2HCRTR2EPHX2 | |
| Alcohol SCHEMBL6702863 | 0.97 | MIF (0.33) | MIFNR1H2 | |
| SCHEMBL31070837 | 0.88 | MIF (0.33) | MIFNR1H2 | |
| SCHEMBL15887309 | 0.88 | MIF (0.33) | MIFNR1H2 | |
| SCHEMBL4015355 | 0.88 | MIF (0.33) | MIFNR1H2 | |
| SCHEMBL22043547 | 0.88 | CYP1A2 (0.39) | MIFHCRTR2EPHX2 | |
| SCHEMBL6125270 | 0.88 | MIF (0.34) | MIFHCRTR2EPHX2 | |
| SCHEMBL4188806 | 0.87 | MIF (0.34) | MIFHCRTR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109574939-B | Preparation method of rosuvastatin sodium | 安徽省庆云医药股份有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-109574999-B | Preparation method of pitavastatin calcium intermediate | 安徽省庆云医药股份有限公司 | 2022-03-08 | — | — | CN | claimed |
| EP-2526099-B1 | IMPROVED PROCESS FOR THE PREPARATION OF AMIDE INTERMEDIATES AND THEIR USE THEREOF | MSN LAB LTD (IN) | 2016-03-30 | — | — | EP | claimed |
| US-20120323005-A1 | Process For The Preparation Of Amide Intermediates And Their Use Thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2012-12-20 | — | — | US | claimed |
| WO-2011086584-A2 | IMPROVED PROCESS FOR THE PREPARATION OF AMIDE INTERMEDIATES AND THEIR USE THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-07-21 | — | — | WO | claimed |
| EP-0577040-B1 | Process for the preparation of (3R,5S)-6-hydroxy-3,5-O-isopropylidene-3,5-dihydroxy-hexanoic acid, tert.-butyl ester | HOECHST AG (DE) | 1997-09-24 | — | — | EP | claimed |
| EP-0577040-A2 | Process for the preparation of (3R,5S)-6-hydroxy-3,5-O-isopropylidene-3,5-dihydroxy-hexanoic acid, tert.-butyl ester | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-01-05 | — | — | EP | claimed |
| CN-115894431-B | Preparation method of statin drug intermediate | 南京欧信医药技术有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118561803-A | Method for preparing rosuvastatin calcium intermediate by micro-channel reactor | 江苏阿尔法集团盛基药业(宿迁)有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-118515672-A | Medicine with microcirculation improving effect and preparation method thereof | 南京医科大学 | 2024-08-20 | — | — | CN | disclosed |
| US-11814355-B2 | Method for synthesizing pitavastatin t-butyl ester | ANHUI QINGYUN PHARMACEUTICAL AND CHEMICAL CO., LTD. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| CN-115611848-A | Synthetic method of rosuvastatin calcium intermediate | 江苏阿尔法药业股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| EP-0577040-A2 | Process for the preparation of (3R,5S)-6-hydroxy-3,5-O-isopropylidene-3,5-dihydroxy-hexanoic acid, tert.-butyl ester | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-01-05 | — | — | EP | disclosed |
| EP-0577040-A2 | Process for the preparation of (3R,5S)-6-hydroxy-3,5-O-isopropylidene-3,5-dihydroxy-hexanoic acid, tert.-butyl ester | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-01-05 | — | — | EP | disclosed |
| US-5248793-A | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate | WARNER-LAMBERT COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
| EP-0553213-A1 | PROCESS FOR THE SYNTHESIS OF (4R-CIS)-1,1-DIMETHYLETHYL-6-CYANOMETHYL-2,2-DIMETHYL-1,3-DIOXANE-4-ACETATE. | WARNER LAMBERT CO (US) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992006968-A1 | PROCESS FOR THE SYNTHESIS OF (4R-CIS)-1,1-DIMETHYLETHYL-6-CYANOMETHYL-2,2-DIMETHYL-1,3-DIOXANE-4-ACETATE | WARNER-LAMBERT COMPANY (US) | 1992-04-30 | — | — | WO | disclosed |
| US-5103024-A | PROCESS FOR THE SYNTHESIS OF (4R-CIS)-1,1-DIMETHYLETHYL 6-CYANOMETHYL-2,2-DIMETHYL-1,3-DIOXANE-4-ACETATE | WARNER-LAMBERT COMPANY (US) | 1992-04-07 | — | — | US | disclosed |
| EP-0418648-A1 | 4-Hydroxytetrahydropyran-2-ones as well as the corresponding dehydroxy carbon acid derivatives, salts and esters, process for their preparation, pharmaceutical preparations as well as precursors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814355-B2 | Method for synthesizing pitavastatin t-butyl ester | SSTR4, DPP4, VIP | MIF 1064/4885NR1H2 3671/4885HCRTR2 2131/4885 |
| US-20120323005-A1 | Process For The Preparation Of Amide Intermediates And Their Use Thereof | CETP, LCAT, APOB | MIF 4406/4885NR1H2 29/4885HCRTR2 3285/4885 |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | MIF 2406/4885NR1H2 2376/4885HCRTR2 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.